Presentation of the guidance and posology framework relevant to therapeutic radiopharmaceuticals

Vanessa Fradin-Da Ros

Product Lead Oncology and Radiopharmaceuticals Human Medicines Division









EMA is

- A decentralised agency of the EU
- Responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU
- A networking organisation whose activities involve thousands of experts from across Europe carrying out the work of EMA's scientific committees

EMA protects human & animal health

- Facilitate development and access to medicines
- Evaluate applications for marketing authorisation
 - 7 Scientific committees providing independent recommendations on medicines based on a comprehensive scientific evaluation of data
 - Centralised procedure
 - EMA referral procedures
 - Coordination of inspections
- Monitor the safety of medicines across their life cycle
- Provide reliable information on human and veterinary medicines in lay language



EMA does not

× || >> || >> || Evaluate all marketing authorisation applications (MAAs) of all medicines in the EU



Evaluate clinical trials applications (CTAs)



Develop treatment guidelines

Provide medical advice

Ų

...

Develop laws concerning medicines

Issue marketing authorisation (MA)

Stakeholder Engagement

- To optimise the Agency's public service role in improving human and animal health, EMA systematically integrates multi-stakeholder engagement by design into its key activities and strategic priorities
- EMA engages with stakeholders to:
 - ensure that EMA decisions are well informed, meet stakeholders' needs and reach them
 - harness the widest expertise available
 - raise awareness and understanding of EMA's evolving role and its work
 - reinforce confidence and trust in the scientific and regulatory outcomes and in the EU system



A few principles

The summary of product characteristics (SmPC) is the basis of information for healthcare professionals (HCPs) on how to use the medicine safely and effectively.

The therapeutic indication reflect in which disease/condition and target population the benefit / risk (B/R) balance is established to be positive, before presenting other conditions for use and presenting information on benefits (5.1) or risks (4.3, 4.4, 4.8 and others).

The European public assessment report (EPAR)) presents the B/R assessment of the medicine itself. Apart from the B/R presented in the EPAR, there is the relative B/R assessment (vs other products, mainly under remit of HTA bodies) and the B/R assessment at individual level.

PI provides HCPs and Patients with conditions for use of the product in the approved indication together with information on benefits and risks (based on relevant data submitted by the applicant / MAH to support the MA) to support therapeutic choice and safe and effective use at individual level.



Product-information (PI) requirements: EMA guidance

- Practical advice on how to draw up the PI for human medicines (incl. summary of product characteristics (SmPC), labelling and package leaflet (PL)).
- Explains the content + standard headings +the most commonly used standard statements and terms in all official EU languages + Icelandic & Norwegian AND defines the format and layout for the product information.
- EMA's guidance is without prejudice to:
 - any final positions from the Agency, the <u>CHMP</u> or European institutions relating to the contents of the documents;
 - the binding nature of the relevant legislation;
 - any legal interpretations given by the EC or the CJ of the EU.

Guideline on SmPC / posology

R	evision
NOTICE TO APPLICANTS	
A GUIDELINE ON	
SUMMARY OF PRODUCT CHARACTERISTICS	
(SuPC)	
September 2009	

<u>EudraLex</u>

Volume 2C: Regulatory guidelines
Guideline on SmPC Rev.2



How to prepare and review a summary of product characteristics: <u>here</u>



<u>SmPC training presentation</u>: Section 4.2: Posology and method of administration



NTA vol 2C, A GUIDELINE ON SUMMARY OF PRODUCT CHARACTERISTICS (SmPC) September 2009

Introduction :

- Principles applicable to all medicinal products.
- Depend on the scientific knowledge on the medicinal product, the legal basis of a marketing authorisation and public health needs.
- Deviation should therefore be justified in the relevant Overview or Summary in the MAA.



NTA vol 2C, A GUIDELINE ON SUMMARY OF PRODUCT CHARACTERISTICS (SmPC) September 2009

- Specific requirements for radiopharmaceuticals in terms of :
 - DOSIMETRY (section 11): Full details of internal radiation dosimetry to be included.
 - INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS (section 12): additional detailed instructions for extemporaneous preparation and QC + where appropriate, maximum storage time during which any intermediate preparation such as an eluate or the ready-to-use pharmaceutical will conform to its specifications. Special instructions relating to the disposal of containers and unused contents should also be included.



This project has received funding from the European Commission under Service Contract N° ENER/2022/NUCL/SI2.869532.0

Guideline on SmPC / posology

Scientific guidelines with SmPC recommendations

Table of contents	
Table of contents	
1. Clinical efficacy and safety	
2. Quality and biological	
3. Non-clinical	

lote: the tables below only include adopted scientific guidelines which refer specifically to the SmPC.

Scientific guidelines with SmPC recommendations – Radiopharmaceuticals - <u>EMA/813125/2012 rev. 6</u>

Under

A contract of the second of the sec

EMA webpage on <u>Clinical efficacy and safety:</u> <u>radiopharmaceuticals and diagnostic agents</u>

Committee for Medicinal Products for Human Use (CHMP)

Guideline on core SmPC and Package Leaflet for Radiopharmaceuticals

Draft Agreed by Radiopharmaceuticals drafting group	February 201
Adoption by CHMP for release for consultation	17 March 201
End of consultation (deadline for comments)	25 April 201
Adoption by CHMP	23 September 201

Guideline on core SmPC and Package Leaflet for Radiopharmaceuticals - <u>EMA/CHMP/167834/2011</u>



Guideline on core SmPC and Package Leaflet for Radiopharmaceuticals

Covers all radiopharmaceuticals incl. kits for radiopharmaceutical preparation

Describes the information to be included in the SmPC and PL for Radiopharmaceuticals

To be read in conjunction with Article 11 of Directive 2001/83/EC as amended, and the introduction and general principles (4) and part I of the Annex I to Directive 2001/83/EC as amended.



• 4.2 Posology and method of administration

Posology

<Adults>

[Posology should as a general rule

- state a suggested activity range
- be based on a patient of average weight (70 kg).

The activity range should be stated in MBq in round numbers. A statement that "other activities may be justifiable" may also be considered appropriate.

Reference to European procedural guidelines should be made if required.]

§implerad

Renal impairment / Hepatic impairment

<Careful consideration of the activity to be administered is required since an increased radiation exposure is possible in these patients.>

Paediatric population

[Paediatric dosing regimens, when applicable, should be clearly stated when an indication exists in this subgroup. If there are data available which are not sufficient to support an indication in the paediatric population, these data may be summarised in section 5.1 of the SmPC with a cross reference from section 4.2, Paediatric population. Reference could be made to relevant data proposed by bodies specialised in radiation protection and/or nuclear medicine.]

<The use in children and adolescents has to be considered carefully, based upon clinical needs and

assessing the risk/benefit ratio in this patient group. The activities to be administered to children and to

adolescents may be calculated according to [include here relevant data proposed by bodies specialised in

radiation protection and/or nuclear medicine]. >

[When the minimum recommended activity in the EANM dosage card for paediatrics is different than the baseline activity, it should be stated here.]



Method of administration

[Product specific, it should be specified if multidose or for single use only.]

[For kits for radiopharmaceutical preparation:] <This medicinal product should be reconstituted before administration to the patient.>

<For instructions on <reconstitution> <dilution> <extemporary preparation> of the medicinal product before administration, see section <12>.>

<For patient preparation, see section 4.4.>

[For a diagnostic radiopharmaceutical intended for imaging or for a therapeutic radiopharmaceutical allowing imaging biodistribution]

<Image acquisition>

[General recommendations should be given about the recommended (minimal) number of imaging times, the delay between administration and imaging, some particular types of acquisition that are recommended in all or some of the indicated clinical settings, such as tomoscintigraphy SPECT, dynamic acquisition (rapid change of biodistribution over time), fusion with another imaging modality ...]



• 4.4 Specials warnings and precautions for use

(...)

Individual benefit/risk justification

[The as low as reasonably achievable (ALARA) statement should be included in every radiopharmaceutical:] For each patient, the radiation exposure must be justifiable by the likely benefit.

The activity administered should in every case be as low as reasonably achievable to obtain the required <diagnostic information> <therapeutic effect>.



Therapeutic RPs (V10) authorised centrally (CAPs)

CAP	Indication high level summary		
Quadramet (samarium SM-153 lexidronam pentasodium)	bone pain		
Zevalin (ibritumomab tiuxetan)	NHL & follicular lymphoma		
Yttriga (yttrium (90Y) chloride)	radiolabelling of carrier molecules		
Xofigo (radium-223)	castration-resistant prostate cancer		
Lumark (lutetium (¹⁷⁷ Lu) chloride)	radiolabelling of carrier molecules		
EndolucinBeta (lutetium (¹⁷⁷ Lu) chloride)	radiolabelling of carrier molecules		
LUTATHERA (lutetium (177Lu) oxodotreotide)	Gastro-entero-pancreatic neuroendocrine tumors		
Pluvicto (lutetium (177Lu) vipivotide tetraxetan)	PSMA+ metastatic castration resistant prostate cancer		
Lutetium (177Lu) chloride Billev (lutetium (177Lu) chloride)	radiolabelling of carrier molecules		



Lumark (lutetium (¹⁷⁷Lu) chloride) 80Gbq/ml

• 4.2 Posology and method of administration

Lumark is only to be used by specialists experienced with *in vitro* radiolabelling.

Posology

The quantity of Lumark required for radiolabelling and the quantity of the medicinal product to be radiolabelled with lutetium(177Lu) that is subsequently administered will depend on the medicinal product to be radiolabelled and its intended use. Refer to the Summary of Product Characteristics/package leaflet of the particular medicinal product to be radiolabelled. (...)



Lumark (lutetium (¹⁷⁷Lu) chloride) 80Gbq/ml

• 4.4 Special warnings and precautions for use

Individual benefit/risk justification

For each patient, the radiation exposure must be justifiable by the likely benefit. The activity administered should in every case be as low as reasonably achievable to obtain the required therapeutic effect. Lumark is not to be administered directly to the patient but must be used for the radiolabelling of carrier molecules, such as monoclonal antibodies, peptides or other substrates. (...)



Lutathera (lutetium (¹⁷⁷Lu) oxodotreotide)

• 4.2 Posology and method of administration

Lutathera should be administered only by persons authorised to handle radiopharmaceuticals in designated clinical settings (see section 6.6) and after evaluation of the patient by a qualified physician.

Posology

Adults

The recommended treatment regimen of Lutathera in adults consists of 4 infusions of 7 400 MBq each. The recommended interval between each administration is 8 weeks (±1 week). Information on dose modifications to manage severe or intolerable adverse drug reactions is given in the respective section



Lutathera (lutetium (¹⁷⁷Lu) oxodotreotide)

• 4.4 Special warnings and precautions for use

Individual benefit-risk justification

For each patient, the radiation exposure must be justifiable by the likely benefit. The activity administered should in every case be as low as reasonably achievable to obtain the required therapeutic effect.

Given the mechanism of action and the tolerance profile of Lutathera, it is not recommended to start treatment with Lutathera in patients with somatostatin receptor-negative or mixed visceral lesions according to somatostatin receptor imaging. (...)



Pluvicto (lutetium (¹⁷⁷Lu) vipivotide tetraxetan)



• 4.2 Posology and method of administration

Important safety instructions

Pluvicto should be administered only by persons authorised to handle radiopharmaceuticals in designated clinical settings (see section 6.6) and after evaluation of the patient by a qualified physician.

Radiopharmaceuticals, including Pluvicto, should be used by or under the control of healthcare professionals who are qualified by specific training and experience in the safe use and handling of radiopharmaceuticals, and whose experience and training have been approved by the appropriate governmental agency authorised to license the use of radiopharmaceuticals.

Patient identification

Patients should be identified for treatment by PSMA imaging.

Posology

The recommended treatment regimen of Pluvicto is 7 400 MBq intravenously every 6 weeks (±1 week) for up to a total of 6 doses, unless there is disease progression or unacceptable toxicity.

Medical castration with a gonadotropin-releasing hormone (GnRH) analogue should be continued during treatment in patients not surgically castrated.

Pluvicto (lutetium (¹⁷⁷Lu) vipivotide tetraxetan)

• 4.4 Special warnings and precautions for use

Individual benefit/risk justification

For each patient, the radiation exposure must be justifiable by the likely benefit. The activity administered should in every case be as low as reasonably achievable to obtain the required therapeutic effect.(...)



Lutetium (¹⁷⁷Lu) chloride Billev (lutetium (¹⁷⁷Lu) chloride)

• 4.2 Posology and method of administration

Lutetium (¹⁷⁷Lu) chloride Billev is only to be used by specialists experienced with *in vitro* radiolabelling.

Posology

The quantity of Lutetium (¹⁷⁷Lu) chloride Billev required for radiolabelling and the quantity of lutetium (¹⁷⁷Lu)-labelled medicinal product that is subsequently administered will depend on the medicinal product radiolabelled and its intended use. Refer to the Summary of Product Characteristics/package leaflet of the particular medicinal product to be radiolabelled. (...)



Lutetium (¹⁷⁷Lu) chloride Billev (lutetium (¹⁷⁷Lu) chloride)

• 4.4 Special warnings and precautions for use

Individual benefit/risk justification

For each patient, the radiation exposure must be justifiable by the likely benefit. The activity administered should in every case be as low as reasonably achievable to obtain the required therapeutic effect.

Lutetium (¹⁷⁷Lu) chloride Billev is not to be administered directly to the patient but must be used for the radiolabelling of carrier molecules, such as monoclonal antibodies, peptides, vitamins or other substrates.



Reminder on legal status of guidelines

Guidelines are to be considered as a **harmonised EU position** on **how to interpret and apply requirements** to demonstrate quality, safety and efficacy set out in the directives.


Guidelines are to be followed to facilitate development, assessment, approval and control of medicinal products in the EU.

Deviations must be duly justified in the dossier at the time MA submission.



Guidelines

Radiopharmaceuticals focus group – Oncology European Specialised Expert Community (<u>ESEC</u>)



Procedure for EU guidelines and related documents within the pharmaceutical legislative framework, March 2009 (EMEA/P/24143/2004 Rev. 1 corr):

• Selection of topic and inclusion in the relevant work programme • Appointment of rapporteur Development of concept paper Adoption and release for public consultation of concept paper • Preparation of initial draft guideline • Adoption and release for public consultation of draft guideline Collection of comments • Preparation of final version of guideline Adoption of final guideline for publication Implementation plerad

28

Concept paper development, adoption for consultation

- CP conveys the need for discussion of a specific issue but does not elaborate on the solutions
- Adopted for public consultation, usually 2-3 months
- Content is the basis for the future Guideline or Reflection Paper
- SIMPLERAD project conclusions to contribute to inform future regulatory discussions including when drafting the CP





Conclusions



Specificities of radiopharmaceuticals considered in relevant Guideline including posology.



PI: provides HCPs and Patients with conditions for use of the product in the approved indication together with information on benefits and risks (based on relevant data submitted by applicant / MAH to support the MA) to support therapeutic choice and safe and effective use at individual level.



Activities for the Radiopharmaceuticals DG were put on hold from 2019 till May 2023 (BCP)



Concept paper on evaluation of therapeutic RPs in oncology (ONCWP work plan for 2024)



Radiopharmaceuticals focus group belonging to Oncology European Specialised Expert Community (<u>ESEC</u>) restarted work in November 2023



Thank you

